Latest On Xeris Pharmaceuticals, Inc (XERS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-09 20:02 EST | News | Xeris Pharmaceuticals GAAP EPS of -$0.12 beats by $0.05, revenue of $33.2M beats by $2.43M | N/A |  |
| 2023-05-09 20:01 EST | News | Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-08 17:08 EST | News | Xeris Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-04-18 16:47 EST | News | Xeris stock trades higher on US patent covering XeriSol formulations | N/A | |
| 2023-03-30 18:12 EST | News | Regeneron in research agreement with Xeris Biopharma | N/A | |
About Xeris Pharmaceuticals, Inc (XERS):
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglyce read more...mia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
General
- Name Xeris Pharmaceuticals, Inc
- Symbol XERS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 180
- Fiscal Year EndDecember
- IPO Date2018-06-21
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.xerispharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 9.75
- Price/Book (Most Recent Quarter) 6.69
- Enterprise Value Revenue 8.88
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.22
- Next Year EPS Estimate -$0.64
- Next Quarter EPS Estimate -$0.46
- Operating Margin -401%
- Return on Assets -38%
- Return on Equity -378%
- Revenue 20.44 million
- Earnings Per Share -$4.11
- Revenue Per Share $0.48
- Gross Profit 11.21 million
- Quarterly Earnings Growth 284.8%
Highlights
- Market Capitalization 285.17 million
- EBITDA -94216000
- PE Ratio -7.03
- Analyst Target Price $11.25
- Book Value Per Share $0.57
Share Statistics
- Shares Outstanding 66.32 million
- Shares Float 55.38 million
- % Held by Insiders 238%
- % Held by Institutions 54.31%
- Shares Short 8.51 million
- Shares Short Prior Month 5.89 million
- Short Ratio 2.98
- Short % of Float 18%
- Short % of Shares Outstanding 17%
Technicals
- Beta 1.97
- 52 Week High $7.94
- 52 Week Low $1.45
- 50 Day Moving Average 5.64
- 200 Day Moving Average 5.29
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Xeris Pharmaceuticals, Inc (XERS) Dividend Calendar:
Xeris Pharmaceuticals, Inc (XERS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Xeris Pharmaceuticals, Inc (XERS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Xeris Pharmaceuticals, Inc (XERS) Chart:
Xeris Pharmaceuticals, Inc (XERS) News:
Below you will find a list of latest news for Xeris Pharmaceuticals, Inc (XERS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Xeris Pharmaceuticals, Inc (XERS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest XERS Trades:
Xeris Pharmaceuticals, Inc (XERS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-08 | 8-K (Current report) | |
| 2020-09-25 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-09-16 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-09-02 | DEF 14A (Other definitive proxy statements) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 8-K (Current report) | |
| 2020-08-18 | PRE 14A (Other preliminary proxy statements) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-01 | 8-K (Current report) | |
| 2020-07-01 | 8-K (Current report) | |
Xeris Pharmaceuticals, Inc (XERS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xeris Pharmaceuticals, Inc (XERS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 238%
Institutional Ownership: 5431%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-13 | John Patrick Jr Shannon | Officer | Buy | 22,000.00 | 3.55 | 77,994.40 | 117,493.00 | |
| 2020-05-08 | Paul R Edick | Officer | Buy | 33,000.00 | 3.00 | 99,000.00 | 401,134.00 | |
| 2020-05-08 | John Patrick Jr Shannon | Officer | Buy | 7,886.00 | 3.20 | 25,219.43 | 95,493.00 | |
| 2020-03-13 | Beth Hecht | Officer | Buy | 4,000.00 | 1.97 | 7,880.00 | 57,083.00 | |
| 2020-02-14 | Paul R Edick | Officer | Buy | 20,000.00 | 4.15 | 83,000.00 | 183,134.00 | |
| 2020-02-14 | John Patrick Jr Shannon | Officer | Buy | 12,048.00 | 4.15 | 49,999.20 | 22,607.00 | |
| 2020-02-14 | Barry M. Deutsch | Officer | Buy | 9,639.00 | 4.15 | 40,001.85 | 39,359.00 | |
| 2020-02-14 | KENNETH ERLAND JOHNSON | Officer | Buy | 2,410.00 | 4.15 | 10,001.50 | 6,115.00 | |
| 2020-02-14 | Beth Hecht | Officer | Buy | 4,000.00 | 4.15 | 16,600.00 | 8,083.00 | |
| 2020-01-31 | KENNETH ERLAND JOHNSON | Officer | Buy | 20,000.00 | 26,115.00 | | ||
| 2020-01-31 | Paul R Edick | Officer | Buy | 185,000.00 | 368,134.00 | | ||
| 2020-01-31 | STEVEN PRESTRELSKI | Chief Scientific Officer | Buy | 15,000.00 | 436,824.00 | | ||
| 2020-01-31 | Beth Hecht | Officer | Buy | 45,000.00 | 53,083.00 | | ||
| 2020-01-31 | John Patrick Jr Shannon | Officer | Buy | 65,000.00 | 87,607.00 | | ||
| 2020-01-31 | Barry M. Deutsch | Officer | Buy | 50,000.00 | 89,359.00 | | ||
| 2020-01-13 | STEVEN PRESTRELSKI | Chief Scientific Officer | Sell | 10,000.00 | 5.50 | 54,992.00 | 421,824.00 | |
| 2019-12-31 | John Patrick Jr Shannon | Officer | Buy | 438.00 | 5.99 | 2,623.62 | 10,559.00 | |
| 2019-12-31 | KENNETH ERLAND JOHNSON | Officer | Buy | 286.00 | 5.99 | 1,713.14 | 3,705.00 | |
| 2019-12-31 | Beth Hecht | Officer | Buy | 459.00 | 5.99 | 2,749.41 | 4,083.00 | |
| 2019-11-25 | Paul R Edick | Officer | Buy | 17,935.00 | 8.55 | 153,283.27 | 172,935.00 | |